Table 2

Randomised control trials of adverse reactions following VZV vaccination (<8 weeks)

Study	Population(s)	Fever	Local reaction	Varicella like rash
Weibel et al 26		956 (1–14 y)	>38.9°C oral	(v) 27% at 48 h	(v) 4% at 8 wk
Weibel et al 26			(v) = (p) = 2% per wk	(p) 19% at 48 h	(p) 2% at 8 wk
Englund et al 56		111 (15–18 mth)	>37.8°C oral	7% at 48 h	(v) = (p) = 2% at 6 wk
Englund et al 56		4 lost to follow up	(v) 35% (p) 36%	(p) 4% at 48 h
Levin et al 57		202 (55–87 y)	>38°C	1st injection 6%	6/202 3%
Levin et al 57			<1%	2nd 0%	Level II evidence
Kuter et al 46		757 (13–54 y)	>37.8°C oral	1st injection 19%	Post 1st: 8%
		57 lost to follow up		1st injection 10%	2nd 31%	Post 2nd: <1%
		57 lost to follow up		2nd 7%	p > 0.05	Post 2nd: <1%
Ramiksissoon et al 58		200 (9–24 mth)	—		Zero all groups		Total 2/200 1%
		18 lost to follow up
		Dose titration study
Tan et al 21		191 (9–24 mth)	Total 23%	Total 24%		Total 6/191 3%
Tan et al 21		Dose titration study	p > 0.05	Total 24%		Total 6/191 3%
Watson et al 47		111 (12–19 mth)	Total 6%	—	Total 5/111 4.5%
		MMRV + (p) vs			3.5% vs 5.6%
		MMR + (v)
Varis and Vesikari28		493 (10–30 mth)		Not defined	Not noted	To 4 weeks
Varis and Vesikari28		493 (10–30 mth)		Zero		(v) 4.5% (p) 3.7%
Ngaiet al 31		2196 (1–12 y)	⩾38.9°C oral	24% vs 26%	4% vs 1%
		238 lost to follow up	1 dose 15%		p < 0.001
			2 doses 11%
Rothstein et al 29		150 (1–6 y)	>38.9°C oral	To 6 weeks	To 6 weeks
Rothstein et al 29		Dose titration study	10–16%, p > 0.05	12–18%	2–4%
White et al 49	494 (1–2.5 y)	⩾38.9°C oral	To 6 weeks	To 6 weeks
(1st study)	MMRV + (p)	25% vs 22%	14% vs 12%	7% both groups
	MMR + (v)
White et al 49	318 (1–3.5 y)	⩾38.9°C oral	To 6 weeks	To 6 weeks
(2nd study)	2 lost to follow up	23% vs 15%	2.5% vs 2%	17% vs 16%
	MMRV vs MMR + (v)
Berger et al 55		200 (55–88 y)		Not defined	To 6 weeks	To 6 weeks
Berger et al 55		200 (55–88 y)		Zero at 72 h	(v) 36% (c) 66%	1/200

(v), varicella vaccine group; (p), placebo group; (c), control group.